SSTR2 and neoplasm: A second-generation of SSTR2 antagonists that include DOTA-JR11 showed higher tumor uptake when combined with 68Ga-DOTA (1.3 times), or 68Ga-NODAGA (1.7 times) as compared with DOTA analogs (109).